

Genomic Analysis of Cardiac Surgery–Associated *Mycobacterium chimaera* Infections, United States

Nabeeh A. Hasan, L. Elaine Epperson,
Adrian Lawsin, Rachael R. Rodger,
Kiran M. Perkins, Alison Laufer Halpin,
K. Allison Perry, Heather Moulton-Meissner,
Daniel J. Diekema, Matthew B. Crist,
Joseph F. Perz, Max Salfinger,
Charles L. Daley, Michael Strong

A surgical heater–cooler unit has been implicated as the source for *Mycobacterium chimaera* infections among cardiac surgery patients in several countries. We isolated *M. chimaera* from heater–cooler units and patient infections in the United States. Whole-genome sequencing corroborated a risk for these units acting as a reservoir for this pathogen.

Mycobacterium chimaera is a species in the *Mycobacterium avium* complex (MAC) (1). MAC is the most frequently reported cause of nontuberculous mycobacterium (NTM) infection in the United States, although disseminated *M. chimaera* infections are relatively rare (2). In 2012, investigators in Switzerland found that some patients with disseminated *M. chimaera* infections had undergone open-chest cardiac surgeries, during which they were exposed to heater–cooler units (HCUs) (3). These devices, Stöckert 3T Heater–Cooler Units (LivaNova PLC, <https://www.livanova.com>; formerly Sorin Group Deutschland GmbH), manufactured in Germany, were unknowingly contaminated with *M. chimaera* (4,5). In the same year, a Pennsylvania hospital identified a cluster of invasive *M. chimaera* infections among open-chest cardiac surgery patients exposed to LivaNova 3T HCUs contaminated with *M. chimaera* (6), which prompted notification of ≈1,300 patients with exposure to these units (7). Additional cases of disseminated *M. chimaera* infection among cardiac surgery patients have emerged worldwide, with evidence

implicating bioaerosols produced by contaminated LivaNova 3T HCUs as the source of post–cardiac surgery *M. chimaera* infections (8,9). We report the relationships among HCU-associated isolates from patients and LivaNova 3T HCUs in the United States and their context among the global outbreak.

The Study

During 2015–2016, we collected NTM isolates from 3T HCU water (n = 38 isolates) and suspected patient cases (n = 24 isolates) from 8 US locations. We identified isolates and conducted high-throughput whole-genome sequencing using the Illumina Miseq system (<https://www.illumina.com>). We selected Pennsylvania isolate 2015-2271 (USA_PA_PAT_9) for Pacific Biosciences (<https://www.pacb.com>) single-molecule real-time sequencing (10). We downloaded publicly available *M. chimaera* genomes from isolates collected in Australia, Denmark, Italy, New Zealand, the United Kingdom, and Switzerland from the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA). We included Zürich CHE_HCU_1 isolate as a representative of the genotype isolated from HCUs, patients, and manufacturing sites in Europe (9). For each isolate, we mapped the sequence reads to the *M. chimaera* strain CDC 2015-22-71 reference genome (GenBank accession no. NZ_CP019221.1) to detect single-nucleotide polymorphisms (SNPs) (Appendix, <http://wwwnc.cdc.gov/EID/article/25/3/18-1282-App1.pdf>).

We reconstructed phylogenetic relationships among *M. chimaera* isolates collected from post–cardiac surgery patients and HCUs in 8 locations across the United States, as well as HCU-associated strains from Australia, New Zealand, and Europe (Table; Appendix Figure 1). We compared all HCU-associated isolates with 7 *M. chimaera* respiratory isolates obtained from US patients with no history of cardiac surgery. We identified 18,190 SNPs in the 3.82-Mb core genome (62.8% of the reference genome) among 126 *M. chimaera* isolates.

The NeighborNet splitstree (Appendix) of *M. chimaera* showed 3 groups (HCU1, HCU2, and non-HCU; Figure 1). Clade HCU1 (n = 112 isolates; Figure 2) is a discrete cluster composed entirely of HCU-associated isolates from case-patients and HCUs (mean pairwise distance 4 SNPs, range 0–23 SNPs; Appendix Figure 2) from Australia,

Author affiliations: National Jewish Health, Denver, Colorado, USA (N.A. Hasan, L.E. Epperson, R.R. Rodger, M. Salfinger, C.L. Daley, M. Strong); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A. Lawsin, K.M. Perkins, A.L. Halpin, K.A. Perry, H. Moulton-Meissner, M.B. Crist, J.F. Perz); University of Iowa, Iowa City, Iowa, USA (D.J. Diekema)

DOI: <https://doi.org/10.3201/eid2503.181282>

Table. *Mycobacterium chimaera* isolated from HCUs, suspected patient case(s), and non-HCU-associated *M. chimaera* isolates in Australia, Europe, New Zealand, and the United States*

Location	No. isolates	No. clinical	No. HCU	Status	Genotypes/Location	No. HCU1 genotypes (%)	NCBI BioProject no.	Reference
Iowa 1	9	3	6	HCU	1	9 (100)	PRJNA345021	(11); this study
Iowa 2	3	0	3	HCU	1	3 (100)	PRJNA345021	This study
Kentucky	1	0	1	HCU	1	1 (100)	PRJNA345021	This study
Massachusetts 1	4	0	4	HCU	1	4 (100)	PRJNA345021	This study
Michigan	17	8	9	HCU	1	17 (100)	PRJNA345021	This study
Minnesota	1	1	0	HCU	1	1 (100)	PRJNA345021	This study
Pennsylvania 1†	25	10	15	HCU	2	23 (92)	PRJNA344472	(11); this study
Virginia	2	2	0	HCU	1	2 (100)	PRJNA345021	This study
Australia 1	6	0	6	HCU	1	6 (100)	PRJEB15375	(12)
Australia 2	13	1	12	HCU	3	11 (84.6)	PRJEB15375	(12)
Australia 3	7	2	5	HCU	3	5 (71.4)	PRJEB15375	(12)
Australia 4	10	2	8	HCU	2	9 (90)	PRJEB15375	(12)
Denmark	4	0	4	HCU	1	4 (100)	PRJEB18427	(13)
New Zealand 1	2	0	2	HCU	1	2 (100)	PRJEB15375	(12)
New Zealand 2	3	0	3	HCU	1	3 (100)	PRJEB15375	(12)
New Zealand 3	5	0	5	HCU	1	5 (100)	PRJEB15375	(12)
New Zealand 4	2	0	2	HCU	1	2 (100)	PRJEB15375	(12)
United Kingdom	3	0	3	HCU	1	3 (100)	PRJNA324238	(13)
Zürich	2	0	2	HCU	2	1 (50)	PRJNA313770, PRJNA314007	(9)
Italy	1	1	0	Non-HCU	1	0	PRJEB18427	(9)
Maryland	1	1	0	Non-HCU	1	0	PRJNA345021	This study
Massachusetts 2	1	1	0	Non-HCU	1	0	PRJNA319839	This study
North Carolina	1	1	0	Non-HCU	1	0	PRJNA345021	This study
Pennsylvania 2	1	1	0	Non-HCU	1	0	PRJNA345021	This study
Tennessee	2	2	0	Non-HCU	1	0	PRJNA319839	This study
Texas	2	2	0	Non-HCU	1	0	PRJNA345021	This study
Total		38	90			112 (95)‡		

*US isolates were collected during 2015–2016. Status refers to HCU-associated isolates (HCU) collected directly from Stöckert 3T Heater–Cooler Units (LivaNova PLC, <https://www.livanova.com>; formerly Sorin Group Deutschland GmbH) or from patients with suspected HCU-derived *M. chimaera*, and isolates from pulmonary NTM patients without history of HCU exposure (non-HCU). HCU, heater–cooler unit; NCBI, National Center for Biotechnology Information.


†Denotes the location from which the 2 samples (USA_PA_HCU_0, 2015–06–01; and USA_PA_PAT_10, 2015–22–65) did not pass the genomics quality control assessment and were excluded from the analyses.


‡Percentage was derived from the number of HCU1 genotype isolates in the number of isolates collected directly from LivaNova 3T HCU or suspected patient cases.

Denmark, New Zealand, Switzerland, the United Kingdom, and the United States. Clade HCU2 was composed of 3 HCU-associated *M. chimaera* isolates from Switzerland (2) and Australia (AUS_HCU_30 and AUS_HCU_31). The mean difference among HCU2 isolates was 21.3 SNPs (range 19–25 SNPs; Appendix). Clade 3 was composed of US non-HCU-associated isolates (non-HCU). Two

HCU-associated patient isolates from Australia (mean non-HCU-associated isolate pairwise SNPs 52, range 3–111 SNPs; Appendix) were unclustered. The mean distance between HCU1 and international HCU isolates was 13.58 SNPs (range 0–521 SNPs; Appendix Figure 3); the mean distance between HCU1 and non-HCU-associated isolates was 510.5 SNPs (range 506–610 SNPs; Appendix).

Figure 1. Neighbor Net splitstree of *Mycobacterium chimaera* isolates: relationships between *M. chimaera* isolates (n = 124) mapped against the *M. chimaera* strain CDC 2015–22–71 heater–cooler unit (HCU) reference genome (18,190 single-nucleotide polymorphisms [SNPs] in 3,815,639 core positions). Isolates were grouped with a threshold of ≤500 SNPs to the nearest cluster. Clustered HCU isolates, including the reference strain CDC 2015–22–71, comprise the HCU1 cluster (n = 112) and HCU2 (n = 3). Unclustered isolates include Australian (AUS) HCU isolates (n = 2), USA non-HCU isolates (n=8), and the type strain FI-01069. Scale bar indicates SNPs.





Whole-genome sequencing of US HCU-associated *M. chimaera* isolates and their comparisons with global HCU-associated isolates provides further evidence for point-source contamination and worldwide dissemination of a *M. chimaera* strain (3–5). Twenty-two of 24 (92%) US patient isolates associated with HCU exposure during cardiac surgery phylogenetically clustered with international HCU-derived and post-cardiac surgery patient

Our analyses revealed that all US *M. chimaera* isolates associated with LivaNova 3T HCU exposure genetically cluster with HCU1 genotype isolates implicated in the global outbreak of post-cardiac surgery *M. chimaera* infections. The HCU2 cluster was not observed in the United States but included 2 isolates from HCUs in Australia, as well as a representative genotype of *M. chimaera* found in HCUs in Europe and at the HCU production site. Consistent with previous findings, this finding suggests the international circulation of a second, less plentiful, strain in the manufacturing site water system (8).

These observations support the hypothesis that the LivaNova 3T HCU design provided suitable conditions for both NTM colonization and aerosolization, particularly by *M. chimaera*. Even though production site contamination with *M. chimaera* has been confirmed, the medical community needs to remain alert for HCU-associated NTM infections involving other species (4). HCUs are vulnerable to contamination from in-hospital water sources, use of improper water sources, and improper maintenance, each of which may increase the risk of infection by NTM (including *M. abscessus*, *M. chelonae*, and *M. goodii*, in addition to *M. chimaera*) (6). Contaminated HCUs may contain NTM-contaminated biofilms. Furthermore, water from the LivaNova 3T HCUs can become aerosolized during normal function, leading to introduction of potentially infectious particles into the sterile field, onto graft materials, or into the open chest cavity during cardiac surgery. The death rate for HCU-associated *M. chimaera* infections has been reported to be 50%; the latent period to diagnosis can be up to 5 years postsurgery (4,6,7,9,10), further emphasizing necessary diligence on the part of physicians and cardiac surgery patients to monitor for symptoms of disseminated NTM infection.

Our study has some limitations in methodology. We did not obtain samples from every US hospital that reported LivaNova 3T HCU-associated *M. chimaera* cases; no submitting hospital collected all 3 types of samples (HCUs, non-HCU samples, and suspected case-patients); and HCU samples were not collected by a single person or according to a standardized collection protocol. Despite these limitations, this analysis of US HCU-associated *M. chimaera* isolates clearly shows the clustering of isolates from epidemiologically linked US cases to international LivaNova 3T HCU *M. chimaera* isolates and the HCU1 genotype found within the LivaNova manufacturing site.

In conclusion, the application of WGS has advanced our understanding of *M. chimaera* present in US LivaNova 3T HCUs and patient cases after the initial analysis of suspected cases in Pennsylvania and Iowa. Given the innate drug resistance and the high death rate of HCU-associated *M. chimaera* infections, it remains imperative for hospitals to follow Food and Drug Administration guidelines (9) and

the manufacturer's instructions to minimize the risk of patient infection. In addition, clinicians should monitor patients who have had cardiac surgery using LivaNova 3T HCUs for signs and symptoms of NTM infection to enable early diagnosis and treatment.

N.A.H., L.E.E., C.L.D., and M.S. acknowledge the support of the National Jewish Health NTM Center for Excellence and the Colorado Cystic Fibrosis Foundation Research Development Program (grant no. NICK15R0); M.S., N.A.H., and L.E.E. acknowledge the support of the Boettcher Foundation; and A.L., A.L.H., M.B.C., J.F.P., H.M.M., K.M.P., and K.A.P. acknowledge the support of the US Centers for Disease Control and Prevention.

About the Author


Dr. Hasan is a researcher at the Center for Genes, Environment and Health at National Jewish Health, Denver, Colorado, USA. His main research focuses on nontuberculous *Mycobacteria* comparative genomics to discover genetic markers associated with pathoadaptation and conduct outbreak surveillance.

References

1. van Ingen J, Turenne CY, Tortoli E, Wallace RJ Jr, Brown-Elliott BA. A definition of the *Mycobacterium avium* complex for taxonomical and clinical purposes, a review. *Int J Syst Evol Microbiol*. 2018;68:3666–77. <http://dx.doi.org/10.1099/ijsem.0.003026>
2. Tan N, Sampath R, Abu Saleh OM, Tweet MS, Jevremovic D, Alniemi S, et al. Disseminated *Mycobacterium chimaera* infection after cardiothoracic surgery. *Open Forum Infect Dis*. 2016;3:ofw131. <http://dx.doi.org/10.1093/ofid/ofw131>
3. Achermann Y, Rössle M, Hoffmann M, Deggim V, Kuster S, Zimmermann DR, et al. Prosthetic valve endocarditis and bloodstream infection due to *Mycobacterium chimaera*. *J Clin Microbiol*. 2013;51:1769–73. <http://dx.doi.org/10.1128/JCM.00435-13>
4. Sax H, Bloemberg G, Hasse B, Sommerstein R, Kohler P, Achermann Y, et al. Prolonged outbreak of *Mycobacterium chimaera* infection after open-chest heart surgery. *Clin Infect Dis*. 2015;61:67–75. <http://dx.doi.org/10.1093/cid/civ198>
5. Kohler P, Kuster SP, Bloemberg G, Schulthess B, Frank M, Tanner FC, et al. Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated *Mycobacterium chimaera* infections subsequent to open heart surgery. *Eur Heart J*. 2015;36:2745–53. <http://dx.doi.org/10.1093/eurheartj/ehv342>
6. Food and Drug Administration. Nontuberculous mycobacterium (NTM) infections associated with heater-cooler devices (HCD) during cardiothoracic surgery. 2016 Meeting Materials of the Circulatory System Devices Panel [cited 2018 Mar 29]. <https://www.fda.gov/AdvisoryCommittees/CommitteesMeeting-Materials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/ucm485091.htm>
7. WellSpan Health System. WellSpan York Hospital notifies open-heart surgery patients of possible infection risk. 2015 [cited 2018 Mar 30]. <https://www.wellspan.org/news/story/15810>
8. Haller S, Höller C, Jacobshagen A, Hamouda O, Abu Sin M, Monnet D, et al. Contamination during production of heater-cooler units by *Mycobacterium chimaera* potential cause for invasive cardiovascular infections: results of an outbreak investigation

- in Germany, April 2015 to February 2016. Euro Surveill. 2016;21:30215. <http://dx.doi.org/10.2807/1560-7917.ES.2016.21.17.30215>
9. van Ingen J, Kohl TA, Kranzer K, Hasse B, Keller PM, Katarzyna Szafrńska A, et al. Global outbreak of severe *Mycobacterium chimaera* disease after cardiac surgery: a molecular epidemiological study. Lancet Infect Dis. 2017;17:1033–41. [http://dx.doi.org/10.1016/S1473-3099\(17\)30324-9](http://dx.doi.org/10.1016/S1473-3099(17)30324-9)
 10. Hasan NA, Lawsin A, Perry KA, Alyanak E, Toney NC, Malecha A, et al. Complete genome sequence of *Mycobacterium chimaera* strain CDC 2015-22-71. Genome Announc. 2017; 5:e00693-17. <http://dx.doi.org/10.1128/genomeA.00693-17>
 11. Perkins KM, Lawsin A, Hasan NA, Strong M, Halpin AL, Rodger RR, et al. Notes from the field: *Mycobacterium chimaera* contamination of heater-cooler devices used in cardiac surgery—United States. MMWR Morb Mortal Wkly Rep. 2016;65:1117–8. <http://dx.doi.org/10.15585/mmwr.mm6540a6>
 12. Williamson D, Howden B, Stinear T. *Mycobacterium chimaera* spread from heating and cooling units in heart surgery. N Engl J Med. 2017;376:600–2. <http://dx.doi.org/10.1056/NEJMc1612023>
 13. Chand M, Lamagni T, Kranzer K, Hedge J, Moore G, Parks S, et al. Insidious risk of severe *Mycobacterium chimaera* infection in cardiac surgery patients. Clin Infect Dis. 2017;64:335–42. <http://dx.doi.org/10.1093/cid/ciw754>

Address for correspondence: Nabeeh A. Hasan, National Jewish Health Center for Genes, Environment and Health, 1400 Jackson St A632, Denver, CO 80206, USA; email: hasann@NJHealth.org



**Originally published
in November 2008**

etymologia revisited

Chimera

[ki-mir'ə]

From the Greek *Khimaira*, Latin *Chimaera*; she-goat. In Greek mythology: a composite creature with the body and head of a lion, a goat's head rising from its back, and a serpent's tail. In science: an individual organism whose body contains cell populations derived from different zygotes, of the same or different species. Each population of cells keeps its own character, and the resulting animal is a mixture of tissues. Chimera also refers to a substance created from proteins or genes of 2 species, as by genetic engineering. Chimerism is rare in humans; ≈40 cases have been reported.

Source: Dorland's illustrated medical dictionary, 31st edition. Philadelphia: Saunders; 2007; <http://www.merriam-webster.com>; <http://www.medicinenet.com/script/main/hp.asp>

https://wwwnc.cdc.gov/eid/article/14/11/e1-1411_article